Co-infection and Cancer (R21 Clinical Trial Not Allowed)
This grant funds research on how co-infections contribute to cancer development to improve prevention and treatment strategies for infection-related cancers.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 16, 2025 (New) | March 16, 2025 (Renewal/Resubmission/Revision) | June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year.
Summary: Supports exploratory mechanistic and epidemiologic research on how co-infections contribute to cancer development, to inform prevention and treatment of infection-related cancers.
Key Information: Clinical trials are not allowed; studies focused solely on HIV or a single pathogen are not eligible.
Description
This NIH funding opportunity supports exploratory and developmental (R21) research projects investigating the roles of co-infection in cancer etiology, progression, and prevention. The goal is to advance mechanistic and epidemiologic understanding of how concurrent or sequential infections by two or more agents (viruses, bacteria, parasites, or other microorganisms) contribute to carcinogenesis. The program aims to uncover new pathways and mechanisms that may inform strategies for prevention, early detection, and treatment of infection-related cancers.
Preference is given to studies involving co-infections with known oncogenic agents (excluding HIV) and those that offer novel opportunities for cancer prevention or treatment. Projects should be innovative, break new ground, or extend previous discoveries in new directions.
